Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis

Camille V. EdwardsDepartment of Medicine, Harlem Hospital Center, New York, NY, USA,

Julia GouldDivision of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA,

Arielle L. LangerDivision of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA,

Markus MaparaDivision of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA,

Jai RadhakrishnanDivision of Nephrology and

Mathew S. MaurerDivision of Cardiology, Columbia University Medical Center, New York, NY, USA, and

Shahzad RazaDivision of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA,

John G. MearsDivision of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA,

Jonathan WallGraduate School of Medicine, University of Tennessee, Knoxville, TN, USA

Alan SolomonGraduate School of Medicine, University of Tennessee, Knoxville, TN, USA

Suzanne LentzschDivision of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA, Correspondence[email protected]

show all

References

Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol. 2000;157:1239–46
PubMed Web of Science ®Google Scholar
Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res. 2003;9:3831S–8S
PubMed Web of Science ®Google Scholar
Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, Smith GT, Wells KJ. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010;116:2241–4
PubMed Web of Science ®Google Scholar
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, et al. New criteria for response to treatment in Immunoglobulin Light Chain Amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9
PubMed Web of Science ®Google Scholar
Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Rosin MV, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325–32
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date